F 992

Drug Profile

F 992

Latest Information Update: 24 Sep 2002

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Class
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Diabetes insipidus; Urinary incontinence

Most Recent Events

  • 24 Sep 2002 Discontinued - Clinical-Phase-Unknown for Urinary incontinence in Sweden (IV-infusion)
  • 24 Sep 2002 Discontinued - Clinical-Phase-Unknown for Diabetes insipidus in Sweden (IV-infusion)
  • 13 Jun 2000 Investigation in Diabetes insipidus in Sweden (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top